CN114755340A - 血清中盐酸阿霉素的检测方法 - Google Patents
血清中盐酸阿霉素的检测方法 Download PDFInfo
- Publication number
- CN114755340A CN114755340A CN202210431357.XA CN202210431357A CN114755340A CN 114755340 A CN114755340 A CN 114755340A CN 202210431357 A CN202210431357 A CN 202210431357A CN 114755340 A CN114755340 A CN 114755340A
- Authority
- CN
- China
- Prior art keywords
- sample
- doxorubicin hydrochloride
- methanol
- serum
- aqueous solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 title claims abstract description 52
- 229960002918 doxorubicin hydrochloride Drugs 0.000 title claims abstract description 52
- 238000000034 method Methods 0.000 title claims abstract description 39
- 210000002966 serum Anatomy 0.000 title claims abstract description 31
- 239000007864 aqueous solution Substances 0.000 claims abstract description 25
- 238000002414 normal-phase solid-phase extraction Methods 0.000 claims abstract description 23
- 238000012360 testing method Methods 0.000 claims abstract description 21
- 238000002156 mixing Methods 0.000 claims abstract description 15
- 239000012224 working solution Substances 0.000 claims abstract description 12
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 claims abstract description 10
- 230000010355 oscillation Effects 0.000 claims abstract description 8
- 239000000945 filler Substances 0.000 claims abstract description 7
- 238000000746 purification Methods 0.000 claims abstract description 5
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 102
- 238000002386 leaching Methods 0.000 claims description 26
- 239000011148 porous material Substances 0.000 claims description 24
- 239000000243 solution Substances 0.000 claims description 19
- 239000003480 eluent Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000012071 phase Substances 0.000 claims description 13
- 238000001514 detection method Methods 0.000 claims description 12
- 238000010828 elution Methods 0.000 claims description 11
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 8
- 230000003213 activating effect Effects 0.000 claims description 7
- 238000012856 packing Methods 0.000 claims description 5
- 238000007789 sealing Methods 0.000 claims description 5
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 4
- 235000019253 formic acid Nutrition 0.000 claims description 4
- 238000001819 mass spectrum Methods 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000003463 adsorbent Substances 0.000 claims description 3
- 238000004366 reverse phase liquid chromatography Methods 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 238000004811 liquid chromatography Methods 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 abstract description 3
- 230000004907 flux Effects 0.000 abstract description 2
- 238000005516 engineering process Methods 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 6
- 238000011002 quantification Methods 0.000 description 5
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 4
- 239000010931 gold Substances 0.000 description 4
- 229910052737 gold Inorganic materials 0.000 description 4
- 229960000907 methylthioninium chloride Drugs 0.000 description 4
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 3
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 229940016667 resveratrol Drugs 0.000 description 3
- 235000021283 resveratrol Nutrition 0.000 description 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001917 fluorescence detection Methods 0.000 description 2
- 229910021397 glassy carbon Inorganic materials 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000002552 multiple reaction monitoring Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000006479 redox reaction Methods 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
- G01N30/14—Preparation by elimination of some components
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/30—Control of physical parameters of the fluid carrier of temperature
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/32—Control of physical parameters of the fluid carrier of pressure or speed
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/34—Control of physical parameters of the fluid carrier of fluid composition, e.g. gradient
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
- G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/86—Signal analysis
- G01N30/8675—Evaluation, i.e. decoding of the signal into analytical information
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N2030/042—Standards
- G01N2030/045—Standards internal
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
- G01N2030/062—Preparation extracting sample from raw material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/30—Control of physical parameters of the fluid carrier of temperature
- G01N2030/3007—Control of physical parameters of the fluid carrier of temperature same temperature for whole column
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/32—Control of physical parameters of the fluid carrier of pressure or speed
- G01N2030/324—Control of physical parameters of the fluid carrier of pressure or speed speed, flow rate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/34—Control of physical parameters of the fluid carrier of fluid composition, e.g. gradient
- G01N2030/342—Control of physical parameters of the fluid carrier of fluid composition, e.g. gradient fluid composition fixed during analysis
Landscapes
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Library & Information Science (AREA)
- Engineering & Computer Science (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
Description
母离子 | 子离子 | ID | 去簇电压(V) | 碰撞电压(V) | 出口电压(V) |
544.3 | 396.8 | 盐酸阿霉素-1 | 60 | 16 | 12 |
544.3 | 379 | 盐酸阿霉素-2 | 60 | 25 | 9.5 |
229.3 | 135.1 | 白藜芦醇 | 60 | 21 | 12 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210431357.XA CN114755340A (zh) | 2022-04-22 | 2022-04-22 | 血清中盐酸阿霉素的检测方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210431357.XA CN114755340A (zh) | 2022-04-22 | 2022-04-22 | 血清中盐酸阿霉素的检测方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114755340A true CN114755340A (zh) | 2022-07-15 |
Family
ID=82333783
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210431357.XA Pending CN114755340A (zh) | 2022-04-22 | 2022-04-22 | 血清中盐酸阿霉素的检测方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114755340A (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010105112A1 (en) * | 2009-03-11 | 2010-09-16 | Hemaquest Pharmaceuticals, Inc. | Detection of short-chain fatty acids in biological samples |
CN111521705A (zh) * | 2020-05-05 | 2020-08-11 | 大连润生康泰医学检验实验室有限公司 | 一种血清中胆汁酸的富集方法 |
CN112782318A (zh) * | 2021-02-08 | 2021-05-11 | 嘉兴学院 | 一种用hplc检测盐酸阿霉素的方法 |
-
2022
- 2022-04-22 CN CN202210431357.XA patent/CN114755340A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010105112A1 (en) * | 2009-03-11 | 2010-09-16 | Hemaquest Pharmaceuticals, Inc. | Detection of short-chain fatty acids in biological samples |
CN111521705A (zh) * | 2020-05-05 | 2020-08-11 | 大连润生康泰医学检验实验室有限公司 | 一种血清中胆汁酸的富集方法 |
CN112782318A (zh) * | 2021-02-08 | 2021-05-11 | 嘉兴学院 | 一种用hplc检测盐酸阿霉素的方法 |
Non-Patent Citations (9)
Title |
---|
刘奕明;林爱华;邓时贵;欧润妹;巫志峰;: "液相色谱-串联质谱法测定兔血浆阿霉素浓度", 药物分析杂志, no. 08 * |
唐利安;陈知航;侯禹男;单成启;刘萍;程远国;王忠伟;: "隐形盐酸阿霉素脂质体注射液药代动力学的实验研究", 中国临床药理学杂志, no. 04 * |
张文萍;甘梦月;马妍妮;党宏万;: "LC-MS/MS法测定大鼠血浆中阿霉素的药物浓度及应用", 中国医药导报, no. 35 * |
李敬涛等: "HPLC-MS/MS法同时测定大鼠血浆中多柔比星及其代谢产物的浓度", 中国临床药理学杂志, vol. 36, no. 2, pages 194 * |
李瑞萍等: "固相萃取亲水作用色谱法测定人体血浆中表阿霉素", 药物分析杂志, vol. 28, no. 4, pages 5 * |
王婷;孙亮;王东亮;甘雅玲;胡西学;郭宏博;何芳菲;王昱青;蒋乔;: "超高效液相色谱-串联质谱法测定小鼠肿瘤组织中阿霉素药物浓度", 分析仪器, no. 01 * |
童珊珊, 余江南, 徐希明, 杨琴, 沈玉萍, 朱源: "反相高效液相色谱法测定阿霉素在小鼠血清中的含量", 江苏大学学报(医学版), no. 06 * |
蔡迪鸣;张爽;刘艳杰;: "反相高效液相色谱荧光检测法测定血浆或肝组织中阿霉素含量", 中国现代药物应用, no. 07 * |
赵芹;万义;罗飞;梁贵伦;吴晓冬;徐小平;: "绿原酸联用阿霉素犬的药物动力学研究", 华西药学杂志, no. 05 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106248838B (zh) | 高通量液相色谱串联质谱的检测方法以及检测4种儿茶酚胺代谢物的方法 | |
EP1962097A1 (en) | Mass spectrometric quantitative detection of methyl malonic acid and succinic acid using hilic on a zwitterionic stationary phase | |
CN111024874A (zh) | 液相色谱质谱联用法定量检测儿茶酚胺及其代谢物的方法 | |
Wang et al. | Automated solid-phase extraction hyphenated to voltammetry for the determination of quercetin using magnetic nanoparticles and sequential injection lab-on-valve approach | |
US20150212055A1 (en) | Sensitive Method for Measuring Cis-Diol Containing Compounds in Plasma Using 2D-LC-MS/MS | |
CN112782328A (zh) | 检测尿液中儿茶酚胺及其代谢物的方法、试剂盒及其应用 | |
CN111289637A (zh) | 一种检测苹果汁中展青霉素的方法 | |
Santos-Neto et al. | Simultaneous analysis of five antidepressant drugs using direct injection of biofluids in a capillary restricted-access media-liquid chromatography–tandem mass spectrometry system | |
Tang et al. | On-line multi-residue analysis of fluoroquinolones and amantadine based on an integrated microfluidic chip coupled to triple quadrupole mass spectrometry | |
Chen et al. | Solid phase extraction based microfluidic chip coupled with mass spectrometry for rapid determination of aflatoxins in peanut oil | |
Chen et al. | Technologies to improve the sensitivity of existing chromatographic methods used for bioanalytical studies | |
CN109613144B (zh) | 一种儿茶酚胺类激素的检测方法 | |
Skoglund et al. | Monolithic packed 96‐tips set for high‐throughput sample preparation: determination of cyclophosphamide and busulfan in whole blood samples by monolithic packed 96‐tips and LC‐MS | |
CN110274974B (zh) | 一种血清中肾上腺素类物质的检测方法及其富集材料 | |
CN114594170A (zh) | 一种磁固相萃取结合快速原位衍生化的体内药物分析方法 | |
CN114755340A (zh) | 血清中盐酸阿霉素的检测方法 | |
Benton et al. | Direct and simultaneous quantitation of 5‐aminolaevulinic acid and porphobilinogen in human serum or plasma by hydrophilic interaction liquid chromatography–atmospheric pressure chemical ionization/tandem mass spectrometry | |
Cheng et al. | Improving sensitivity for microchip electrophoresis interfaced with inductively coupled plasma mass spectrometry using parallel multichannel separation | |
Zhou et al. | Determination of azithromycin residue in pork using a molecularly imprinted monolithic microcolumn coupled to liquid chromatography with tandem mass spectrometry | |
CN112903836B (zh) | 体外培育熊胆粉中异丙基-β-D-硫代吡喃半乳糖苷的测定方法 | |
CN112611814B (zh) | 一种干血片中1,5-脱水葡萄糖醇的测定方法 | |
Schelletter et al. | A positive pressure workstation for semi‐automated peptide purification of complex proteomic samples | |
CN114354822A (zh) | 一种基于磁性吸附剂快速提取儿茶酚胺的方法 | |
Namera et al. | Monolithic spin column: a new extraction device for analysis of drugs in urine and serum by GC/MS and HPLC/MS | |
CN108982726B (zh) | 苹果酸在5-甲基及5-羟甲基胞嘧啶核苷分析中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Country or region after: China Address after: Building 4, No.16 Wujing Road, development zone, Dongli District, Tianjin Applicant after: Tianjin Guoke Medical Technology Development Co.,Ltd. Address before: Building 4, No.16 Wujing Road, development zone, Dongli District, Tianjin Applicant before: TIANJIN GUOKE YIGONG TECHNOLOGY DEVELOPMENT Co.,Ltd. Country or region before: China |
|
CB02 | Change of applicant information | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20240407 Address after: Building 4, No.16 Wujing Road, development zone, Dongli District, Tianjin Applicant after: Tianjin Guoke Medical Technology Development Co.,Ltd. Country or region after: China Applicant after: Suzhou Institute of Biomedical Engineering and Technology Chinese Academy of Sciences Address before: Building 4, No.16 Wujing Road, development zone, Dongli District, Tianjin Applicant before: Tianjin Guoke Medical Technology Development Co.,Ltd. Country or region before: China |
|
TA01 | Transfer of patent application right |